Previous 10 | Next 10 |
2024-01-05 11:55:52 ET More on TG Therapeutics TG Therapeutics: The Revenue Beat Isn't What It Looks Like TG Therapeutics: Trying To Fill The Gap Back To $20 TG Therapeutics, Inc. (TGTX) Q3 2023 Earnings Call Transcript TG Therapeutics spikes as Merck KGaA fl...
2024-01-05 11:31:43 ET More on Novo Nordisk Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity Novo Nordisk: Plenty More Room To Run Despite Its Hefty Valuation Novo Nordisk si...
2024-01-05 10:19:54 ET More on Novartis Novartis: Post Investor Day, Higher Guidance Priced In Novartis AG (NVS) 10th Annual ESG Investor Event Conference (Transcript) Sandoz Group: Novartis Spinoff With A Double-Digit EBITDA CAGR Through 2028 Voyager stock s...
2024-01-05 09:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-02 10:46:48 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Voyager Therapeutics (NASDAQ: VYGR ) stock is up by more than 25% today after the company agreed to a licensing deal with Novartis (NYSE: NVS ). Novartis wil...
2024-01-02 08:24:37 ET DENVER, Colo., Jan. 2, 2024 ( www.247marketnews.com )- Voyager Therapeutics, Inc. (NASDAQ: VYGR) reported, this morning, that it formed a strategic collaboration and capsid license agreement with a Novartis AG (NYSE: NVS) to advance potential gene therapies for Hu...
2024-01-02 07:14:42 ET More on Novartis, Voyager Therapeutics, etc. Novartis: Post Investor Day, Higher Guidance Priced In Voyager Therapeutics' Strategic Partnerships And TRACER Technology - Speculative Buy Novartis AG (NVS) 10th Annual ESG Investor Event Conference...
2023-12-29 17:15:31 ET More on bluebird bio, CRISPR Therapeutics, etc. bluebird bio's Lyfgenia: Navigating Commercialization Challenges In SCD Vertex's Pain Game: VX-548 Takes Aim At Neuropathic Battles Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why M...
2023-12-29 14:54:46 ET Summary I review the stocks of five world-class companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends. I point out the specifics of the companies' business models, discuss their pro...
2023-12-28 15:06:23 ET More on AbbVie, Amgen, etc. The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Bristol Myers Squibb: Too Many Headwinds To Ignore, Despit...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...